Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

- PMLiVE

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

If approved, this vaccine will closely challenge Pfizer's Prevnar-13

- PMLiVE

Moderna posts encouraging early data for personalised cancer vaccine

Vaccine tested alongside Merck's Keytruda

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

OLED Medical Technology Saving Patient’s Sight During COVID-19 Pandemic

North East MedTech company secures investment agreement with Japanese tech giant

Onyx Health

- PMLiVE

TikTok and diabetes awareness

The video-sharing platform TikTok has been fostering huge numbers of people documenting the day-to-day reality of their health conditions. From comedy snippets about diagnosis to personal reviews of health tech,...

11 London

Combating Coronavirus Through Reversing Diabetes

The Diabetes Reversal Company has developed a pioneering programme based on sustainable weight loss, evidence-based lifestyle change and one-to-one clinical support to reduce and reverse the effects of Type 2...

Onyx Health

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

- PMLiVE

Merck expands partnership with Zymeworks for multispecific antibodies

New licence agreement builds on existing collaboration

Onyx Health Tackles Diabetes with New Client

Onyx Health have continued to grow as an agency during the COVID-19 downturn, expanding their business into the South East of England by winning a new Surrey based client.

Onyx Health

Covid-19: what could it mean for the diabetic population?

Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it

Wilmington Healthcare

- PMLiVE

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck & Co

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links